Clinical Trial Update: Ofatumumab in AQP4-IgG Seropositive NMOSD [Phase 1, Phase 2]

View source ↗

Summary

This document reports a Phase 1/Phase 2 clinical trial evaluating ofatumumab in AQP4-IgG seropositive NMOSD, with recruitment underway.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Neuromyelitis Optica Spectrum Disorder | Phase 1, Phase 2 | Status: RECRUITING